Black Diamond Therapeutics, Inc.
HealthcareNASDAQ:BDTX · NASDAQ Global Select
-$0.07 today
Vol 2.31M · Avg 1.22M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$43.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.76, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $325.0K | $0 -100.0% | $437.0K | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $69.7M | $0 +100.0% | -$437.0K | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.5% | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $33.6M -34.6% | $51.3M -12.9% | $58.9M -8.6% | $64.4M -33.5% | $96.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $16.6M -39.7% | $27.5M +1.3% | $27.1M -4.5% | $28.4M -5.5% | $30.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $49.8M -36.8% | $78.8M -8.4% | $86.0M -7.3% | $92.8M -26.8% | $126.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $325.0K -5.2% | $343.0K -21.5% | $437.0K -14.0% | $508.0K +147.8% | $205.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $22.7M +132.7% | -$69.3M +15.5% | -$82.0M +9.5% | -$90.7M +27.7% | -$125.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 32.4% | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | $19.9M +125.2% | -$78.8M +8.9% | -$86.5M +6.9% | -$92.8M +26.8% | -$126.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 28.4% | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.1M +86.1% | $2.2M +13.4% | $1.9M -5.3% | $2.0M -41.4% | $3.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.5M -72.6% | $9.1M +126.6% | $4.0M +142.2% | $1.7M +30.0% | $1.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $22.4M +132.1% | -$69.7M +15.5% | -$82.4M +9.6% | -$91.2M +27.4% | -$125.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.0% | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $22.4M +132.1% | -$69.7M +15.5% | -$82.4M +9.6% | -$91.2M +27.4% | -$125.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 32.0% | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +130.7% | -$1 +32.4% | -$2 +25.4% | -$3 +27.4% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +130.7% | -$1 +32.4% | -$2 +25.4% | -$3 +27.4% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $56.9M +3.3% | $55.0M +25.2% | $44.0M +21.3% | $36.2M +0.1% | $36.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.6M +4.6% | $55.0M +25.2% | $44.0M +21.3% | $36.2M +0.1% | $36.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Abeona Therapeutics Inc.
NASDAQ:ABEO
$315.18M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
$257.22M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BDTX generate?
Black Diamond Therapeutics, Inc. (BDTX) reported $70.00M of revenue in fiscal 2025.
Is BDTX profitable?
Black Diamond Therapeutics, Inc. (BDTX) reported $22.37M of net income, with a net margin of 32.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.